Source: FDA, National Drug Code (US) Revision Year: 2020
XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
This indication is approved under accelerated approval based on response rate [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
The recommended dosage of XPOVIO is 80 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity. Administer dexamethasone 20 mg orally with each dose of XPOVIO on Days 1 and 3 of each week. For additional information regarding the administration of dexamethasone, refer to its prescribing information.
The recommended dosage of XPOVIO is 60 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.
Monitor complete blood count (CBC) with differential, standard blood chemistries, body weight, nutritional status, and volume status at baseline and during treatment as clinically indicated. Monitor more frequently during the first three months of treatment [see Warning and Precautions (5.1, 5.2, 5.3, and 5.4)]. Assess the need for dosage modifications of XPOVIO for adverse reactions [see Dosage and Administration (2.5)].
Advise patients to maintain adequate fluid and caloric intake throughout treatment. Consider intravenous hydration for patients at risk of dehydration [see Warnings and Precautions (5.3, 5.4)].
Provide prophylactic antiemetics. Administer a 5-HT3 receptor antagonist and other anti-nausea agents prior to and during treatment with XPOVIO [see Warnings and Precautions (5.3)].
Recommended XPOVIO dosage reduction steps are presented in Table 1.
Table 1. XPOVIO Dosage Reduction Steps for Adverse Reactions:
| Recommended Starting Dosage | Multiple Myeloma | Diffuse Large B-Cell Lymphoma |
|---|---|---|
| 80 mg Days 1 and 3 of each week (160 mg total per week) | 60 mg Days 1 and 3 of each week (120 mg total per week) | |
| First Reduction | 100 mg once weekly | 40 mg Days 1 and 3 of each week (80 mg total per week) |
| Second Reduction | 80 mg once weekly | 60 mg once weekly |
| Third Reduction | 60 mg once weekly | 40 mg once weekly |
| Fourth Reduction | Permanently discontinue | Permanently discontinue |
Recommended dosage modifications for hematologic adverse reactions in patients with multiple myeloma and DLBCL are presented in Table 2 and Table 3, respectively. Recommended dosage modifications for non-hematologic adverse reactions are presented in Table 4.
Table 2. XPOVIO Dosage Modification Guidelines for Hematologic Adverse Reactions in Patients with Multiple Myeloma:
| Adverse Reaction | Occurrence | Action |
|---|---|---|
| Thrombocytopenia [see Warning and Precautions (5.1)] | ||
| Platelet count 25,000 to less than 75,000/mcL | Any | • Reduce XPOVIO by 1 dose level (see Table 1). |
| Platelet count 25,000 to less than 75,000/mcL with concurrent bleeding | Any | • Interrupt XPOVIO. • Restart XPOVIO at 1 dose level lower (see Table 1) after bleeding has resolved. • Administer platelet transfusions per clinical guidelines. |
| Platelet count less than 25,000/mcL | Any | • Interrupt XPOVIO. • Monitor until platelet count returns to at least 50,000/mcL. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Neutropenia [see Warning and Precautions (5.2)] | ||
| Absolute neutrophil count of 0.5 to 1 × 10 9/L without fever | Any | • Reduce XPOVIO by 1 dose level (see Table 1). |
| Absolute neutrophil count less than 0.5 × 10 9/L OR febrile neutropenia | Any | • Interrupt XPOVIO. • Monitor until neutrophil counts return to 1 × 10 9/L or higher. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Anemia | ||
| Hemoglobin less than 8 g/dL | Any | • Reduce XPOVIO by 1 dose level (see Table 1). • Administer blood transfusions per clinical guidelines. |
| Life-threatening consequences | Any | • Interrupt XPOVIO. • Monitor hemoglobin until levels return to 8 g/dL or higher. • Restart XPOVIO at 1 dose level lower (see Table 1). • Administer blood transfusions per clinical guidelines. |
Table 3. XPOVIO Dosage Modification Guidelines for Hematologic Adverse Reactions in Patients with Diffuse Large B-Cell Lymphoma:
| Adverse Reaction | Occurrence | Action |
|---|---|---|
| Thrombocytopenia [see Warning and Precautions (5.1)] | ||
| Platelet count 50,000 to less than 75,000/mcL | Any | • Interrupt one dose of XPOVIO. • Restart XPOVIO at the same dose level. |
| Platelet count 25,000 to less than 50,000/mcL without bleeding | 1st | • Interrupt XPOVIO. • Monitor until platelet count returns to at least 50,000/mcL. • Reduce XPOVIO by 1 dose level (see Table 1). |
| Platelet count 25,000 to less than 50,000/mcL with concurrent bleeding | Any | • Interrupt XPOVIO. • Monitor until platelet count returns to at least 50,000/mcL. • Restart XPOVIO at 1 dose level lower (see Table 1), after bleeding has resolved. • Administer platelet transfusions per clinical guidelines. |
| Platelet count less than 25,000/mcL | Any | • Interrupt XPOVIO. • Monitor until platelet count returns to at least 50,000/mcL. • Restart XPOVIO at 1 dose level lower (see Table 1). • Administer platelet transfusions per clinical guidelines. |
| Neutropenia [see Warning and Precautions (5.2)] | ||
| Absolute neutrophil count of 0.5 to less than 1 × 10 9/L without fever | 1st occurrence | • Interrupt XPOVIO. • Monitor until neutrophil counts return to 1 × 10 9/L or higher. • Restart XPOVIO at the same dose level. |
| Recurrence | • Interrupt XPOVIO. • Monitor until neutrophil counts return to 1 × 10 9/L or higher. • Administer growth factors per clinical guidelines. • Restart XPOVIO at 1 dose level lower (see Table 1). | |
| Absolute neutrophil count less than 0.5 × 10 9/L OR Febrile neutropenia | Any | • Interrupt XPOVIO. • Monitor until neutrophil counts return to 1 × 10 9/L or higher. • Administer growth factors per clinical guidelines. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Anemia | ||
| Hemoglobin less than 8 g/dL | Any | • Reduce XPOVIO by 1 dose level (see Table 1). • Administer blood transfusions per clinical guidelines. |
| Life-threatening consequences | Any | • Interrupt XPOVIO. • Monitor hemoglobin until levels return to 8 g/dL or higher. • Restart XPOVIO at 1 dose level lower (see Table 1). • Administer blood transfusions per clinical guidelines. |
Table 4. XPOVIO Dosage Modification Guidelines for Non-Hematologic Adverse Reactions:
| Adverse Reaction | Occurrence | Action |
|---|---|---|
| Nausea and Vomiting [see Warning and Precautions (5.3)] | ||
| Grade 1 or 2 nausea (oral intake decreased without significant weight loss, dehydration or malnutrition) OR Grade 1 or 2 vomiting (5 or fewer episodes per day) | Any | • Maintain XPOVIO and initiate additional anti-nausea medications. |
| Grade 3 nausea (inadequate oral caloric or fluid intake) OR Grade 3 or higher vomiting (6 or more episodes per day) | Any | • Interrupt XPOVIO. • Monitor until nausea or vomiting has resolved to Grade 2 or lower or baseline. • Initiate additional anti-nausea medications. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Diarrhea [see Warning and Precautions (5.3)] | ||
| Grade 2 (increase of 4 to 6 stools per day over baseline) | 1 st | • Maintain XPOVIO and institute supportive care. |
| 2 nd and subsequent | • Reduce XPOVIO by 1 dose level (see Table 1). • Institute supportive care. | |
| Grade 3 or higher (increase of 7 stools or more per day over baseline; hospitalization indicated) | Any | • Interrupt XPOVIO and institute supportive care. • Monitor until diarrhea resolves to Grade 2 or lower. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Weight Loss and Anorexia [see Warning and Precautions (5.3)] | ||
| Weight loss of 10% to less than 20% OR anorexia associated with significant weight loss or malnutrition | Any | • Interrupt XPOVIO and institute supportive care. • Monitor until weight returns to more than 90% of baseline weight. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Hyponatremia [see Warning and Precautions (5.4)] | ||
| Sodium level 130 mmol/L or less | Any | • Interrupt XPOVIO, evaluate, and provide supportive care. • Monitor until sodium levels return to greater than 130 mmol/L. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Fatigue | ||
| Grade 2 lasting greater than 7 days OR Grade 3 | Any | • Interrupt XPOVIO. • Monitor until fatigue resolves to Grade 1 or baseline. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Ocular Toxicity | ||
| Grade 2, excluding cataract | Any | • Perform ophthalmologic evaluation. • Interrupt XPOVIO and provide supportive care. • Monitor until ocular symptoms resolve to Grade 1 or baseline. • Restart XPOVIO at 1 dose level lower (see Table 1). |
| Grade ≥3 | Any | • Permanently discontinue XPOVIO. • Perform ophthalmologic evaluation. |
| Cataract (Grade ≥2) | Any | • Perform ophthalmologic evaluation. • Reduce XPOVIO by 1 dose level (see Table 1). • Monitor for progression. • Hold XPOVIO dose 24 hours prior to surgery and for 72 hours after surgery. |
| Other Non-Hematologic Adverse Reactions [see Warning and Precautions (5.6)] | ||
| Grade 3 or 4 | Any | • Interrupt XPOVIO. • Monitor until resolved to Grade 2 or lower; restart XPOVIO at 1 dose level lower (see Table 1). |
Each XPOVIO dose should be taken at approximately the same time of day and each tablet should be swallowed whole with water. Do not break, chew, crush, or divide the tablets.
If a dose of XPOVIO is missed or delayed, instruct patients to take their next dose at the next regularly scheduled time.
If a patient vomits a dose of XPOVIO, the patient should not repeat the dose and the patient should take the next dose on the next regularly scheduled day.
Store at or below 30°C (86°F).
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
